Skip to search formSkip to main contentSkip to account menu

alemtuzumab

Known as: MoAb CD52, Anti-CD52 Monoclonal Antibody, alemtuzumab [Chemical/Ingredient] 
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human… 
National Institutes of Health

Related topics

Related topics

20 relations
1.2 ML alemtuzumab 10 MG/ML Injection [Lemtrada]Antibody-Dependent Cellular CytotoxicityCD52 geneCD52 protein, human

Broader (3)

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsCD Antigens

Narrower (6)

CampathCampath 1GCampath 1HCampath 1M

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells.
Highly Cited
2009
Highly Cited
2009
Two Hundred Living Donor Kidney Transplantations Under Alemtuzumab Induction and Tacrolimus Monotherapy: 3‐Year Follow‐Up
Alemtuzumab has been used in off‐label studies of solid organ transplantation. We extend our report of the first 200 consecutive… 
Review
2008
Review
2008
Identification and development of new therapeutics for multiple sclerosis.
Highly Cited
2008
Highly Cited
2008
Calcineurin Inhibitor Withdrawal After Renal Transplantation with Alemtuzumab: Clinical Outcomes and Effect on T‐Regulatory Cells
To address the results of calcineurin inhibitor (CNI) withdrawal after alemtuzumab induction relative to CNI continuation, we… 
Highly Cited
2007
Highly Cited
2007
Reduced‐intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long‐term…
The introduction of reduced‐intensity conditioning (RIC) has enabled the role of allogeneic transplantation to be re‐evaluated in… 
Review
2007
Review
2007
Alemtuzumab (Campath‐1H) in Kidney Transplantation
Kidney transplantation has become the treatment of choice for both the quality of life and survival in patients with end‐stage… 
Highly Cited
2007
Highly Cited
2007
Recovery of Functional Memory T Cells in Lung Transplant Recipients Following Induction Therapy with Alemtuzumab
Profound T‐cell depletion with the monoclonal antibody alemtuzumab facilitates reduced maintenance immunosuppression in abdominal… 
Highly Cited
2005
Highly Cited
2005
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years
Alemtuzumab is a powerful lymphocyte depleting antibody currently being evaluated in solid organ transplantation. This paper… 
Review
2003
Review
2003
Monoclonal antibody therapy for lymphoma.
Highly Cited
2000
Highly Cited
2000
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH conditioning: an effective regimen with low procedure‐related toxicity
Autologous transplantation has an established role in the treatment of lymphoproliferative disorders, but allogeneic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)